The U.K.’s largest listed company, drugs giant AstraZeneca (AZN.L), may soon decide to carve out its China business and list it as a separate entity in Hong Kong or Shanghai, according to the Financial Times. The Anglo-Swedish firm has reportedly been in discussions with bankers on the idea for months, and it is one of … Continue reading AstraZeneca Planning China Business Spin-Off